News | Orthopedic Imaging | May 23, 2017

Asterias MRI Data Shows AST-OPC1 Cells Prevent Cavitation in Severe Spinal Cord Injury Patients

Data indicate disease-modifying aspects of AST-OPC1 may carry long-term benefits related to both recovery and maintenance of motor and sensory function

Asterias MRI Data Shows AST-OPC1 Cells Prevent Cavitation in Severe Spinal Cord Injury Patients

May 23, 2017 — Asterias Biotherapeutics Inc. recently announced new positive serial magnetic resonance imaging (MRI) data from its ongoing AST-OPC1 SCiStar Phase 1/2a clinical trial in patients with severe spinal cord injury.

Study data indicated that:

  • For the five AIS-A patients in the SCiStar study treated with 10 million AST-OPC1 cells (Cohort 2) who also received a serial MRI scan at six months of follow-up, the serial MRI scans indicated no sign of lesion cavities in any patient. These fluid-filled cavities typically form by about three months following severe spinal cord injury and prevent significant recovery of motor and sensory function;
  • For the three patients in Cohort 2 that have also completed 12 months of follow-up, serial MRI scans at 12 months continued to indicate no signs of lesion cavities; and
  • All three AIS-A patients who received a low dose of 2 million cells (Cohort 1) in the SCiStar study also showed no sign of lesion cavities in any patient through 1 year of follow-up.  All three patients are continuing long-term follow-up and will receive additional MRI scans annually.

The MRI results are supportive of the extensive pre-clinical data on AST-OPC1 showing that the cells durably engraft and help prevent cavitation at the injury site. Cavitation is a destructive process that occurs within the spinal cord following spinal cord injuries, and typically results in permanent loss of motor and sensory function. Additionally, a patient with cavitation can develop a condition known as syringomyelia, which results in additional neurological and functional damage to the patient.

Under the study protocol, patients are monitored by MRI scans at regular intervals over 12 months in order to assess status of the injection site and surrounding tissues.

For more information: www.asteriasbiotherapeutics.com

Related Content

Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha
MR Solutions cryogen free preclinical MRI
News | Magnetic Resonance Imaging (MRI) | January 09, 2020
January 9, 2020 — MR Solutions is continuing to expand its support network
The study found that DBN laws helped some women understand they had increased breast density, but not that breast density is associated with a higher risk of breast cancer or that dense breasts limit the ability of mammograms to detect cancer
News | Breast Density | January 09, 2020
January 9, 2020 — A new study suggests that state-mandated notifications on...
prostate cancer UCL study
News | Prostate Cancer | January 03, 2020
January 3, 2020 — Nearly one in six deaths from...